Abstract
Over the past several decades, many antiobesity drugs have been withdrawn from the market due to unanticipated adverse events, often involving cardiotoxicity. This study aimed to evaluate the presence of cardiovascular safety signals with currently marketed antiobesity drugs. We used the US Food and Drug Administration Adverse Event Reporting System (FAERS) database and retrieved data from January 2013 through December 2018. We performed disproportionality analyses to detect cardiovascular safety signals with three antiobesity drugs recently approved for marketing: lorcaserin, naltrexone-bupropion, phentermine, and phentermine-topiramate. Three main cardiovascular outcomes were evaluated: valvular disorders, and pulmonary hypertension (PH) and other cardiovascular events (myocardial infarction, stroke, cardiovascular death, cardiac failure, and arrhythmia). During the evaluated period, a total of 6,787,840 adverse event reports were submitted to FAERS. Of these, 2687 involved lorcaserin, 3960 involved phentermine/phentermine-topiramate, and 2873 involved naltrexone-bupropion. Lorcaserin was associated with a significantly greater proportion of reports of valvular disorders (ROR = 4.39; 95% CI 2.72-5.07). None of the antiobesity...Continue Reading
References
Sep 10, 1998·The New England Journal of Medicine·H JickL E Derby
Jan 11, 2000·Circulation·R B RothmanB L Roth
Apr 20, 2001·The American Journal of the Medical Sciences·E D Michelakis, E K Weir
Jan 5, 2006·Circulation·Robert J Levy
Sep 18, 2007·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Antoine ParienteNicholas Moore
Apr 10, 2009·Pharmacoepidemiology and Drug Safety·A Bate, S J W Evans
May 4, 2010·Cardiovascular Therapeutics·Stephanie W Watts, Robert Patrick Davis
Sep 8, 2010·The New England Journal of Medicine·W Philip T JamesUNKNOWN SCOUT Investigators
Jun 20, 2013·International Journal of Medical Sciences·Koji YoshimuraYasushi Okuno
Jun 26, 2013·International Journal of Medical Sciences·Toshiyuki SakaedaYasushi Okuno
Jun 27, 2013·The Annals of Pharmacotherapy·Joshua W FlemingDaniel M Riche
Feb 24, 2015·Lancet·William H DietzPeter Kopelman
Jan 27, 2016·International Journal of Clinical Practice·D Haslam
Mar 5, 2016·Diabetes, Obesity & Metabolism·A J KrentzM Hompesch
Nov 30, 2016·BMC Medicine·Igho J OnakpoyaJeffrey K Aronson
Feb 2, 2018·Postgraduate Medicine·Dhiren K Patel, Fatima Cody Stanford
Aug 28, 2018·The New England Journal of Medicine·Erin A BohulaUNKNOWN CAMELLIA–TIMI 61 Steering Committee and Investigators